Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 59
- 13F valueReported value at the end of Q2 2026
- $57.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GYRE, Q2 2026
No superinvestor reported holding GYRE at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Gyre Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 (view filing) | Jun 9-18 | 13 daysLate | Ye WeiguoChief Operating Officer | SSale | −11.0K | $6.25 | −$68.7K | −1.5%700.0K after | 3 lots |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Ye WeiguoChief Operating Officer | SSale | −2.80K | $6.17 | −$17.3K | −0.4%700.0K after | |
| Jun 11, 2026 (view filing) | Jun 9-10 | 2 days | Ye WeiguoChief Operating Officer | SSale | −20.9K | $6.16 | −$128.9K | −2.9%700.0K after | 2 lots |
| Jun 8, 2026 (view filing) | Jun 4-5 | 4 days | Ye WeiguoChief Operating Officer | SSale | −35.0K | $6.25 | −$218.6K | −4.8%700.0K after | 2 lots |
| May 27, 2026 (view filing) | May 22-26 | 5 days | Ye WeiguoChief Operating Officer | SSale | −7.50K | $6.09 | −$45.7K | −1.1%700.0K after | 2 lots |
| May 22, 2026 (view filing) | May 20-21 | 2 days | Ye WeiguoChief Operating Officer | SSale | −22.2K | $6.15 | −$136.7K | −3.1%700.0K after | 2 lots |
| May 20, 2026 (view filing) | May 18-19 | 2 days | Ye WeiguoChief Operating Officer | SSale | −9.32K | $6.38 | −$59.4K | −1.3%700.0K after | 2 lots |
| May 18, 2026 (view filing) | May 14-15 | 4 days | Ye WeiguoChief Operating Officer | SSale | −28.7K | $6.79 | −$194.8K | −3.9%700.0K after | 2 lots |
| May 7, 2026 (view filing) | May 5-6 | 2 days | Luo YingChief Executive Officer | SSale | −10.3K | $8.04 | −$82.9K | −0.4%2.57M after | 2 lots10b5-1 |
| May 29, 2025 (view filing) | May 27-28 | 2 days | Ma SongjiangPresident | SSale | −2.56K | $10.23 | −$26.2K | −0.1%2.81M after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Gyre Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SC China Holding Ltd | 3,750,299 | $24.7M | 2.06% | +3,750,299 | New |
| BlackRock, Inc. | 993,943 | $6.55M | 0.00% | +235,313+31.0% | Added |
| Octagon Capital Advisors LP | 954,416 | $6.29M | 0.58% | +954,416 | New |
| Vanguard Capital Management LLC | 876,927 | $5.78M | 0.00% | −107,277−10.9% | Reduced |
| Geode Capital Management, LLC | 532,950 | $3.51M | 0.00% | +101,536+23.5% | Added |
| State Street Corp | 245,402 | $1.62M | 0.00% | +29,076+13.4% | Added |
| Charles Schwab Investment Management Inc | 184,286 | $1.21M | 0.00% | +19,048+11.5% | Added |
| Northern Trust Corp | 169,537 | $1.12M | 0.00% | +35,696+26.7% | Added |
| SBI Securities Co., Ltd. | 166,750 | $1.10M | 0.02% | −4,087−2.4% | Reduced |
| Vanguard Fiduciary Trust Co | 151,073 | $995.6K | 0.00% | +13,391+9.7% | Added |